[
  {
    "ts": null,
    "headline": "Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma",
    "summary": "Biogen faces revenue headwinds, MS franchise erosion, underperforming launches, weak pipeline, and cost-cutting focus. Learn why BIIB stock is upgraded to sell.",
    "url": "https://finnhub.io/api/news?id=1c24417d4417286090801d483a684016a6f0f0707077f7e148a068633d184fcd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768472026,
      "headline": "Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma",
      "id": 138121264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159351618/image_2159351618.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen faces revenue headwinds, MS franchise erosion, underperforming launches, weak pipeline, and cost-cutting focus. Learn why BIIB stock is upgraded to sell.",
      "url": "https://finnhub.io/api/news?id=1c24417d4417286090801d483a684016a6f0f0707077f7e148a068633d184fcd"
    }
  }
]